In honor of the holiday weekend, the Gumshoe is essentially taking a holiday, too. I hope the Americans among you have a great break, if you get one, and that you have a chance to honor the service and memory of so many who have served our country.
But in case you’re looking for some teaser stock action to research, I thought I’d share one with you that has just recently returned to heavy rotation — it’s coming in from several different mailing lists, and many of you have forwarded it to me in the past week.
The ad is still for the Access Group from Marc Lichtenfeld … and it’s still teasing us about the same skin cancer detection stock that it was a few months ago when we first saw it.
The short answer is that the stock is Electro-Optical Sciences (MELA) … and it has done very well in the couple months since we first saw it teased in newsletter ads. At that time it was bouncing around in the $4.5-$5 range, and it’s now close to $8. Certainly one of the stronger performers during that time.
To be fair, it’s still a bit short of the $196 they had as a pie-in-the-sky target, but certainly a nice couple months.
If you’d like to read what I thought about it at the time, and see what your fellow readers commented, you can review that original article here. I still find it hard to get excited about this stock, but I could easily be wrong … and so far, I have been.
Happy reading, and have a great weekend. I’m sure I’ll have some more interesting stocks to write to you about next week.
"reveal" emails? If not,
just click here...
Hi Stock Gumshoe (or is it Travis)??
I’ve signed up and received confirmation that my subscription was confirmed, but have yet to receive any email that is posted on your site, or what you send to your subscribers. I would also like to post a few comments for the rest of your readers as I get a lot of investment email teasers which I’m sure you and the rest of the Gumshoe group would find more than interesting. I believe you are definitely blessed and have been given a Talent from God! I say this because a lot of the Gumshoe readers (from the comments/posts I read)would be broke. Please keep up the great work you are doing. I do not know if you believe in God, but it does not matter to me as I do believe that you have a God given talent, and are making the best use of it!!
God bless you!!
MELA looked good to me. I am long. I can imagine every Doctor in the world wanting one to check skin cancers WITHOUT having to cut flesh and skin off the patient and send it to a lab. And the little device is 100% accurate I hear. Sounds like a dream come true for us all.
http://finance.yahoo.com/q/ta?s=MELA&t=5y&l=on&z=m&q=l&p=m50,m200&a=m26-12-9&c=
For something with that reputation, it’s awfully range bound, & it’s just reversed again trying to break through. Stocks like this aren’t that affected by a market downturn.
These guys also reco’d ARAY at much higher prices, look at it now! http://finance.yahoo.com/q/ta?s=ARAY&t=2y&l=on&z=m&q=l&p=m50,m200&a=&c=
I like their overall service, the price is right ($49.) but there are much better services when it comes to biotechs & the fringe areas of these types of medical tools.
Aside to Fred: Hang in there Fred, I only got my first pick from Travis this past week, he’s still beta-testing some of his website. He’s worth the wait too!
Drive safely folks.
I’m pulling for this stock, which I originally recommended a few months ago for my wife’s retirement portfolio. She bought in at about $4.50. We’re pulling for it not to get rich, but to see it in her derm’s office the next time she gets a mole check.
http://finance.yahoo.com/q/ta?s=CRESY&t=2y&l=on&z=m&q=l&p=m50,m200&a=&c=
On a rainy, stormy pre-memorial Saturday, I glanced at some of your prior researches Travis, CRESY wasn’t the worst by any means, but CROC & SBUX were lu-lus.
http://finance.yahoo.com/q/ta?s=CROX&t=2y&l=on&z=m&q=l&p=&a=&c=SBUX
The CNBC Fast Money show bounced Cramer’s daily re-run & forced Kudlow to move his show back to 7:00pm. But lately, this foursome & their moderator have been too oft wrong lately. The option guy has an older brother who appears irregularly, HE’s the Man! Karen is supposed t/b the fundamental toughie, yet CROX, SBUX & GS have her looking a bit foolish, & that’s just this year.
Anyway, I can’t wait to lower the boom on James Dines, now there’s a Smug & Snobby SOB if ever there was one.
Mr. Roper – How do Dermatologists get paid? For “cutting flesh and skin off of the patient” as you said. If you are a Doc with lowered PPO, HMO, co-pay payments- what would you do? (Well, you would do the test), but the majority of Docs would cut. My client has a cream in FDA 2 testing. (Successfull in Central and South America already). Even though the cream eliminates skin cancer, he is having a tough time convincing Doctors to participate in the test because $3,000 to cut is much more interesting for them than perscribing a $35 tube of cream. My wife was in the study and the stuff works great. (Yes, she uses sunscreen).
You are right, it is not $196, but 70+% is nothing to sneeze at!
Hope you have a good holiday!
Best Wishes,
D4L
I have to agree with farley 5 – yep, I’m cynical – I do believe that the “good” doctors are much outwieghed by the hungry ones, and have found that a $60,000 triple bypass is much prefere by most of the medical fraternity (and hospitals) to an I.V. course of cardio chelation (at about 1/20th of the price).. I fear that the almighty dollar mostly takes precedence over true patient considerations….
But .. it’s good to see a potentially really beneficial product being available for share-purchase-support!
Mike – Sorry this is not about stocks. The Nobel Prize winner, Linus Pauling, worked with two other scientists on arterial sclerosis. They found that patients ready for triple bypass could take Vitamin C, L-Lysine, and L-Proline and eliminate the plaque in three weeks. Since drug companies don’t make money on vitamins, the research is not widely disseminated.
Farley, that isn’t the only reason that patients don’t trust “vitamin therapy.” I have 5 arterial heart stents in two arteries & one elongated branch of the 2nd artery. The first two are uncoated from 1994, the next 3 were inserted in 2004 & are the coated version.
The plaque that wouldn’t give into angioplastry in 1994 was like tile, harder than stone. NO way would
what the good Dr. & his fellow scientists claim have broken down this tile-hardened plaque.
I tried cardio chelation before having the last 3 stent procedure, it FAILED completely & I gave Health Resources of Hueytown, AL more than just a piece of my mind. You must know what kind of plaque
you’re dealing with, hence the angioplastry.
It matters!!!
http://finance.yahoo.com/echarts?s=MELA#symbol=MELA;range=2y
I’m just killing time between church & the BbQ at the pool this afternoon & began reading the MELA Yahoo board postings. A pretty deep board I must say, & I’m wondering what Investment Letter, that charges $2,500./yr, used MELA as the tease? Makes yah wonder when the Access Group from Marc Lichtenfeld (I might’ve erred here, Marc edits Smart Profits for $99./yr or less) & The Motely Fool use MELA in their regular less expensive publications.
This is for farley5. Recently I became interesteed in the less publicised alternative treatments. Could you please give me some more details about the anti-skin cancer cream you mentioned above? If you want, you can email them to sandelm@yahoo.com. Thanks.
SAGENOT,
Having had pentuple bypass “slice & dice” I want to know how you learn what type of plaque you have and
does the chelation therapy affected all blood vessels or are just the heart arteries targeted?
ALL OF YOU
Looking for a online calculator that will let me
set a monthly deposit, interest rate and time.
The calculator will give me the accumulated amount.
Don’t know the correct term to use, but it close to a sinking fund but the ones I found did not let me
set the deposit. Help?
david
Apologies for the typo and grammatical mistakes
in previous posting. I’ll work on my editing
skills.
david
The key to success with this technology is two fold 1) reimbursement for the scan and b) the willingness of dermatologists in USA to use as a a primary tool for melanoma diagnosis.( Or at least support its use in Primary care). Melanoma diagnosis in the dermatologists eyes is not difficult and their sensitivity and specificity for diagnosis is very high. The excisions are reimbursed as standard and dermatologists with a potentially deadly disease on their hands will err on the side of caution and excise; as clinical practice coupled with reimbursement rates make it the best move. However if this technology is used in primary care as a screener then it may have merit as primary care diagnosis is poor for melanoma. Readers should be aware that no diagnostic test is 100% accurate and the sensitivity of Melafind is 98% with specificity of 45% – compare with other automatic diagnostic machines that are of the order of 96% sens with 83% specificity. It has been around for a while, is still in phase III and I wonder if the FDA will be happy releasing to general primary care market with less than 100% sensitivity coupled with a high specificity for this deadly disease. I am unsure whether they have as yet got any data to support reduction in biopsy rates which will be core to their pitch.